nodes	percent_of_prediction	percent_of_DWPC	metapath
Clodronate—PTGS2—thyroid cancer	0.611	1	CbGaD
Clodronate—Osteonecrosis of jaw—Sorafenib—thyroid cancer	0.0169	0.097	CcSEcCtD
Clodronate—SLC25A6—neck—thyroid cancer	0.013	0.137	CbGeAlD
Clodronate—SLC25A5—neck—thyroid cancer	0.0113	0.12	CbGeAlD
Clodronate—SLC25A6—saliva-secreting gland—thyroid cancer	0.0101	0.107	CbGeAlD
Clodronate—SLC25A5—saliva-secreting gland—thyroid cancer	0.00882	0.0933	CbGeAlD
Clodronate—SLC25A5—Interactions of Vpr with host cellular proteins—TPR—thyroid cancer	0.00877	0.073	CbGpPWpGaD
Clodronate—SLC25A6—Interactions of Vpr with host cellular proteins—TPR—thyroid cancer	0.00735	0.0611	CbGpPWpGaD
Clodronate—Myeloid leukaemia—Epirubicin—thyroid cancer	0.00685	0.0394	CcSEcCtD
Clodronate—SLC25A5—trachea—thyroid cancer	0.00681	0.072	CbGeAlD
Clodronate—Myeloid leukaemia—Doxorubicin—thyroid cancer	0.00634	0.0364	CcSEcCtD
Clodronate—SLC25A6—thyroid gland—thyroid cancer	0.00619	0.0654	CbGeAlD
Clodronate—SLC25A4—Interactions of Vpr with host cellular proteins—TPR—thyroid cancer	0.00573	0.0477	CbGpPWpGaD
Clodronate—SLC25A6—head—thyroid cancer	0.00549	0.058	CbGeAlD
Clodronate—SLC25A5—thyroid gland—thyroid cancer	0.00539	0.0569	CbGeAlD
Clodronate—PTGS2—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00534	0.0445	CbGpPWpGaD
Clodronate—SLC25A4—thyroid gland—thyroid cancer	0.00505	0.0533	CbGeAlD
Clodronate—SLC25A5—head—thyroid cancer	0.00478	0.0505	CbGeAlD
Clodronate—Serum creatinine increased—Vandetanib—thyroid cancer	0.00469	0.0269	CcSEcCtD
Clodronate—SLC25A5—Regulation of insulin secretion—PRKAR1A—thyroid cancer	0.00448	0.0373	CbGpPWpGaD
Clodronate—SLC25A4—head—thyroid cancer	0.00448	0.0473	CbGeAlD
Clodronate—Acute myeloid leukaemia—Epirubicin—thyroid cancer	0.00438	0.0252	CcSEcCtD
Clodronate—Hypercalcaemia—Vandetanib—thyroid cancer	0.00415	0.0239	CcSEcCtD
Clodronate—Acute myeloid leukaemia—Doxorubicin—thyroid cancer	0.00405	0.0233	CcSEcCtD
Clodronate—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00401	0.0334	CbGpPWpGaD
Clodronate—SLC25A6—lymph node—thyroid cancer	0.00385	0.0406	CbGeAlD
Clodronate—SLC25A6—Regulation of insulin secretion—PRKAR1A—thyroid cancer	0.00376	0.0313	CbGpPWpGaD
Clodronate—SLC25A5—Integration of energy metabolism—PRKAR1A—thyroid cancer	0.00353	0.0293	CbGpPWpGaD
Clodronate—SLC25A5—lymph node—thyroid cancer	0.00335	0.0354	CbGeAlD
Clodronate—Gastrointestinal symptom NOS—Sorafenib—thyroid cancer	0.00331	0.019	CcSEcCtD
Clodronate—Proteinuria—Vandetanib—thyroid cancer	0.00328	0.0189	CcSEcCtD
Clodronate—Protein urine present—Vandetanib—thyroid cancer	0.00323	0.0186	CcSEcCtD
Clodronate—Hypocalcaemia—Vandetanib—thyroid cancer	0.00315	0.0181	CcSEcCtD
Clodronate—SLC25A4—lymph node—thyroid cancer	0.00313	0.0331	CbGeAlD
Clodronate—SLC25A5—Host Interactions of HIV factors—TPR—thyroid cancer	0.00307	0.0256	CbGpPWpGaD
Clodronate—Creatinine increased—Vandetanib—thyroid cancer	0.00303	0.0174	CcSEcCtD
Clodronate—SLC25A6—Integration of energy metabolism—PRKAR1A—thyroid cancer	0.00295	0.0246	CbGpPWpGaD
Clodronate—SLC25A4—Regulation of insulin secretion—PRKAR1A—thyroid cancer	0.00293	0.0244	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—RET—thyroid cancer	0.0027	0.0225	CbGpPWpGaD
Clodronate—SLC25A6—Host Interactions of HIV factors—TPR—thyroid cancer	0.00258	0.0214	CbGpPWpGaD
Clodronate—Acute leukaemia—Epirubicin—thyroid cancer	0.00251	0.0145	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—THRB—thyroid cancer	0.00251	0.0209	CbGpPWpGaD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—thyroid cancer	0.00239	0.0199	CbGpPWpGaD
Clodronate—SLC25A6—Influenza Infection—TPR—thyroid cancer	0.00235	0.0196	CbGpPWpGaD
Clodronate—Acute leukaemia—Doxorubicin—thyroid cancer	0.00233	0.0134	CcSEcCtD
Clodronate—SLC25A4—Integration of energy metabolism—PRKAR1A—thyroid cancer	0.00231	0.0192	CbGpPWpGaD
Clodronate—Neoplasm malignant—Sorafenib—thyroid cancer	0.00228	0.0131	CcSEcCtD
Clodronate—Proteinuria—Sorafenib—thyroid cancer	0.00221	0.0127	CcSEcCtD
Clodronate—Protein urine present—Sorafenib—thyroid cancer	0.00218	0.0125	CcSEcCtD
Clodronate—PTGS2—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00218	0.0182	CbGpPWpGaD
Clodronate—Cardiac failure—Vandetanib—thyroid cancer	0.00214	0.0123	CcSEcCtD
Clodronate—Hypocalcaemia—Sorafenib—thyroid cancer	0.00212	0.0122	CcSEcCtD
Clodronate—Hyperphosphataemia—Epirubicin—thyroid cancer	0.0021	0.0121	CcSEcCtD
Clodronate—SLC25A4—Host Interactions of HIV factors—TPR—thyroid cancer	0.00201	0.0167	CbGpPWpGaD
Clodronate—SLC25A5—HIV Infection—TPR—thyroid cancer	0.002	0.0166	CbGpPWpGaD
Clodronate—Blood creatinine increased—Vandetanib—thyroid cancer	0.00196	0.0113	CcSEcCtD
Clodronate—Hyperphosphataemia—Doxorubicin—thyroid cancer	0.00195	0.0112	CcSEcCtD
Clodronate—Dehydration—Vandetanib—thyroid cancer	0.00195	0.0112	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Vandetanib—thyroid cancer	0.00185	0.0106	CcSEcCtD
Clodronate—Dysphagia—Vandetanib—thyroid cancer	0.00181	0.0104	CcSEcCtD
Clodronate—Bronchospasm—Vandetanib—thyroid cancer	0.00178	0.0102	CcSEcCtD
Clodronate—SLC25A6—HIV Infection—TPR—thyroid cancer	0.00167	0.0139	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—PRKAR1A—thyroid cancer	0.00167	0.0139	CbGpPWpGaD
Clodronate—Pneumonia—Vandetanib—thyroid cancer	0.00162	0.00933	CcSEcCtD
Clodronate—Hepatic function abnormal—Sorafenib—thyroid cancer	0.00161	0.00929	CcSEcCtD
Clodronate—Renal failure—Vandetanib—thyroid cancer	0.00158	0.00911	CcSEcCtD
Clodronate—Renal failure acute—Sorafenib—thyroid cancer	0.00153	0.00879	CcSEcCtD
Clodronate—PTGS2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00145	0.0121	CbGpPWpGaD
Clodronate—Cardiac failure—Sorafenib—thyroid cancer	0.00145	0.00832	CcSEcCtD
Clodronate—Urinary tract disorder—Vandetanib—thyroid cancer	0.00143	0.00822	CcSEcCtD
Clodronate—Urethral disorder—Vandetanib—thyroid cancer	0.00142	0.00816	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00142	0.0118	CbGpPWpGaD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—SST—thyroid cancer	0.00132	0.011	CbGpPWpGaD
Clodronate—Dehydration—Sorafenib—thyroid cancer	0.00131	0.00755	CcSEcCtD
Clodronate—SLC25A4—HIV Infection—TPR—thyroid cancer	0.00131	0.0109	CbGpPWpGaD
Clodronate—Mediastinal disorder—Vandetanib—thyroid cancer	0.0013	0.0075	CcSEcCtD
Clodronate—Local reaction—Epirubicin—thyroid cancer	0.0013	0.00746	CcSEcCtD
Clodronate—Abdominal pain upper—Sorafenib—thyroid cancer	0.00129	0.00741	CcSEcCtD
Clodronate—PTGS2—trachea—thyroid cancer	0.00128	0.0135	CbGeAlD
Clodronate—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.00124	0.00716	CcSEcCtD
Clodronate—Dysphagia—Sorafenib—thyroid cancer	0.00122	0.00701	CcSEcCtD
Clodronate—Local reaction—Doxorubicin—thyroid cancer	0.0012	0.00691	CcSEcCtD
Clodronate—Serum creatinine increased—Epirubicin—thyroid cancer	0.00117	0.00672	CcSEcCtD
Clodronate—SLC25A5—Disease—TRIM24—thyroid cancer	0.00112	0.00936	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—MINPP1—thyroid cancer	0.00111	0.00922	CbGpPWpGaD
Clodronate—Pneumonia—Sorafenib—thyroid cancer	0.00109	0.00629	CcSEcCtD
Clodronate—Serum creatinine increased—Doxorubicin—thyroid cancer	0.00108	0.00622	CcSEcCtD
Clodronate—Renal failure—Sorafenib—thyroid cancer	0.00107	0.00615	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00107	0.00613	CcSEcCtD
Clodronate—SLC25A5—Disease—CHST14—thyroid cancer	0.00106	0.0088	CbGpPWpGaD
Clodronate—Hypercalcaemia—Epirubicin—thyroid cancer	0.00103	0.00595	CcSEcCtD
Clodronate—Infection—Vandetanib—thyroid cancer	0.00102	0.00587	CcSEcCtD
Clodronate—SLC25A5—Disease—TRIM33—thyroid cancer	0.001	0.00834	CbGpPWpGaD
Clodronate—Skin disorder—Vandetanib—thyroid cancer	0.000999	0.00574	CcSEcCtD
Clodronate—Urinary tract disorder—Sorafenib—thyroid cancer	0.000964	0.00554	CcSEcCtD
Clodronate—Connective tissue disorder—Sorafenib—thyroid cancer	0.000959	0.00552	CcSEcCtD
Clodronate—Urethral disorder—Sorafenib—thyroid cancer	0.000957	0.0055	CcSEcCtD
Clodronate—Hypercalcaemia—Doxorubicin—thyroid cancer	0.000957	0.0055	CcSEcCtD
Clodronate—SLC25A6—Disease—TRIM24—thyroid cancer	0.000942	0.00784	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—NDUFA13—thyroid cancer	0.000941	0.00784	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—MINPP1—thyroid cancer	0.000928	0.00772	CbGpPWpGaD
Clodronate—Dyspnoea—Vandetanib—thyroid cancer	0.000917	0.00527	CcSEcCtD
Clodronate—Dyspepsia—Vandetanib—thyroid cancer	0.000905	0.0052	CcSEcCtD
Clodronate—PTGS2—head—thyroid cancer	0.0009	0.00951	CbGeAlD
Clodronate—Decreased appetite—Vandetanib—thyroid cancer	0.000894	0.00514	CcSEcCtD
Clodronate—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.000888	0.0051	CcSEcCtD
Clodronate—SLC25A6—Disease—CHST14—thyroid cancer	0.000886	0.00737	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—CHST14—thyroid cancer	0.000885	0.00737	CbGpPWpGaD
Clodronate—Mediastinal disorder—Sorafenib—thyroid cancer	0.00088	0.00506	CcSEcCtD
Clodronate—Neoplasm malignant—Epirubicin—thyroid cancer	0.000841	0.00484	CcSEcCtD
Clodronate—SLC25A6—Disease—TRIM33—thyroid cancer	0.00084	0.00699	CbGpPWpGaD
Clodronate—Extravasation—Epirubicin—thyroid cancer	0.000824	0.00474	CcSEcCtD
Clodronate—Abdominal pain—Vandetanib—thyroid cancer	0.000813	0.00467	CcSEcCtD
Clodronate—SLC25A4—SIDS Susceptibility Pathways—HIF1A—thyroid cancer	0.000792	0.00659	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—NDUFA13—thyroid cancer	0.000789	0.00657	CbGpPWpGaD
Clodronate—Anaemia—Sorafenib—thyroid cancer	0.000786	0.00452	CcSEcCtD
Clodronate—Hypocalcaemia—Epirubicin—thyroid cancer	0.000785	0.00451	CcSEcCtD
Clodronate—Oliguria—Epirubicin—thyroid cancer	0.00078	0.00448	CcSEcCtD
Clodronate—Neoplasm malignant—Doxorubicin—thyroid cancer	0.000779	0.00448	CcSEcCtD
Clodronate—Angioedema—Sorafenib—thyroid cancer	0.000777	0.00447	CcSEcCtD
Clodronate—Extravasation—Doxorubicin—thyroid cancer	0.000762	0.00438	CcSEcCtD
Clodronate—Creatinine increased—Epirubicin—thyroid cancer	0.000755	0.00434	CcSEcCtD
Clodronate—SLC25A6—Metabolism—CHST14—thyroid cancer	0.000742	0.00617	CbGpPWpGaD
Clodronate—SLC25A4—Disease—TRIM24—thyroid cancer	0.000735	0.00612	CbGpPWpGaD
Clodronate—Pruritus—Vandetanib—thyroid cancer	0.000728	0.00418	CcSEcCtD
Clodronate—Hypocalcaemia—Doxorubicin—thyroid cancer	0.000726	0.00418	CcSEcCtD
Clodronate—SLC25A4—Metabolism—MINPP1—thyroid cancer	0.000724	0.00603	CbGpPWpGaD
Clodronate—Oliguria—Doxorubicin—thyroid cancer	0.000721	0.00415	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.000719	0.00413	CcSEcCtD
Clodronate—Hepatocellular injury—Epirubicin—thyroid cancer	0.000719	0.00413	CcSEcCtD
Clodronate—SLC25A5—Metabolism—HPGD—thyroid cancer	0.000713	0.00594	CbGpPWpGaD
Clodronate—Diarrhoea—Vandetanib—thyroid cancer	0.000704	0.00405	CcSEcCtD
Clodronate—Creatinine increased—Doxorubicin—thyroid cancer	0.000698	0.00402	CcSEcCtD
Clodronate—SLC25A4—Disease—CHST14—thyroid cancer	0.000691	0.00575	CbGpPWpGaD
Clodronate—Infection—Sorafenib—thyroid cancer	0.000689	0.00396	CcSEcCtD
Clodronate—Skin disorder—Sorafenib—thyroid cancer	0.000674	0.00387	CcSEcCtD
Clodronate—SLC25A5—Disease—TCF7L1—thyroid cancer	0.000669	0.00556	CbGpPWpGaD
Clodronate—Hepatocellular injury—Doxorubicin—thyroid cancer	0.000665	0.00382	CcSEcCtD
Clodronate—Anorexia—Sorafenib—thyroid cancer	0.000661	0.0038	CcSEcCtD
Clodronate—SLC25A4—Disease—TRIM33—thyroid cancer	0.000655	0.00546	CbGpPWpGaD
Clodronate—Vomiting—Vandetanib—thyroid cancer	0.000654	0.00376	CcSEcCtD
Clodronate—Rash—Vandetanib—thyroid cancer	0.000648	0.00373	CcSEcCtD
Clodronate—Dermatitis—Vandetanib—thyroid cancer	0.000648	0.00372	CcSEcCtD
Clodronate—PTGS2—lymph node—thyroid cancer	0.00063	0.00666	CbGeAlD
Clodronate—Dyspnoea—Sorafenib—thyroid cancer	0.000618	0.00356	CcSEcCtD
Clodronate—SLC25A4—Metabolism—NDUFA13—thyroid cancer	0.000616	0.00513	CbGpPWpGaD
Clodronate—Nausea—Vandetanib—thyroid cancer	0.000611	0.00351	CcSEcCtD
Clodronate—Dyspepsia—Sorafenib—thyroid cancer	0.000611	0.00351	CcSEcCtD
Clodronate—Decreased appetite—Sorafenib—thyroid cancer	0.000603	0.00347	CcSEcCtD
Clodronate—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.000599	0.00344	CcSEcCtD
Clodronate—SLC25A6—Metabolism—HPGD—thyroid cancer	0.000598	0.00498	CbGpPWpGaD
Clodronate—Hepatic function abnormal—Epirubicin—thyroid cancer	0.000597	0.00343	CcSEcCtD
Clodronate—SLC25A4—Metabolism—CHST14—thyroid cancer	0.000579	0.00482	CbGpPWpGaD
Clodronate—Renal failure acute—Epirubicin—thyroid cancer	0.000565	0.00325	CcSEcCtD
Clodronate—SLC25A6—Disease—TCF7L1—thyroid cancer	0.00056	0.00466	CbGpPWpGaD
Clodronate—Hepatic function abnormal—Doxorubicin—thyroid cancer	0.000552	0.00318	CcSEcCtD
Clodronate—Urticaria—Sorafenib—thyroid cancer	0.000551	0.00317	CcSEcCtD
Clodronate—Abdominal pain—Sorafenib—thyroid cancer	0.000548	0.00315	CcSEcCtD
Clodronate—Renal impairment—Epirubicin—thyroid cancer	0.000548	0.00315	CcSEcCtD
Clodronate—Cardiac failure—Epirubicin—thyroid cancer	0.000534	0.00307	CcSEcCtD
Clodronate—Renal failure acute—Doxorubicin—thyroid cancer	0.000523	0.00301	CcSEcCtD
Clodronate—Renal impairment—Doxorubicin—thyroid cancer	0.000507	0.00292	CcSEcCtD
Clodronate—Cardiac failure—Doxorubicin—thyroid cancer	0.000495	0.00284	CcSEcCtD
Clodronate—Pruritus—Sorafenib—thyroid cancer	0.000491	0.00282	CcSEcCtD
Clodronate—SLC25A5—Disease—TPR—thyroid cancer	0.000489	0.00407	CbGpPWpGaD
Clodronate—Blood creatinine increased—Epirubicin—thyroid cancer	0.000489	0.00281	CcSEcCtD
Clodronate—Dehydration—Epirubicin—thyroid cancer	0.000485	0.00279	CcSEcCtD
Clodronate—SLC25A5—Disease—PRKAR1A—thyroid cancer	0.000481	0.00401	CbGpPWpGaD
Clodronate—Abdominal pain upper—Epirubicin—thyroid cancer	0.000476	0.00274	CcSEcCtD
Clodronate—Diarrhoea—Sorafenib—thyroid cancer	0.000475	0.00273	CcSEcCtD
Clodronate—SLC25A4—Metabolism—HPGD—thyroid cancer	0.000467	0.00388	CbGpPWpGaD
Clodronate—SLC25A5—Disease—MEN1—thyroid cancer	0.00046	0.00383	CbGpPWpGaD
Clodronate—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00046	0.00265	CcSEcCtD
Clodronate—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000452	0.0026	CcSEcCtD
Clodronate—Dysphagia—Epirubicin—thyroid cancer	0.000451	0.00259	CcSEcCtD
Clodronate—Dehydration—Doxorubicin—thyroid cancer	0.000449	0.00258	CcSEcCtD
Clodronate—Vomiting—Sorafenib—thyroid cancer	0.000441	0.00254	CcSEcCtD
Clodronate—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000441	0.00253	CcSEcCtD
Clodronate—Rash—Sorafenib—thyroid cancer	0.000437	0.00251	CcSEcCtD
Clodronate—SLC25A4—Disease—TCF7L1—thyroid cancer	0.000437	0.00364	CbGpPWpGaD
Clodronate—Dermatitis—Sorafenib—thyroid cancer	0.000437	0.00251	CcSEcCtD
Clodronate—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000426	0.00245	CcSEcCtD
Clodronate—Dysphagia—Doxorubicin—thyroid cancer	0.000417	0.0024	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—LGALS3—thyroid cancer	0.000416	0.00346	CbGpPWpGaD
Clodronate—Nausea—Sorafenib—thyroid cancer	0.000412	0.00237	CcSEcCtD
Clodronate—SLC25A6—Disease—TPR—thyroid cancer	0.00041	0.00341	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—TPR—thyroid cancer	0.00041	0.00341	CbGpPWpGaD
Clodronate—Pneumonia—Epirubicin—thyroid cancer	0.000404	0.00232	CcSEcCtD
Clodronate—SLC25A6—Disease—PRKAR1A—thyroid cancer	0.000403	0.00336	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PRKAR1A—thyroid cancer	0.000403	0.00336	CbGpPWpGaD
Clodronate—Renal failure—Epirubicin—thyroid cancer	0.000395	0.00227	CcSEcCtD
Clodronate—SLC25A6—Disease—MEN1—thyroid cancer	0.000386	0.00321	CbGpPWpGaD
Clodronate—Pneumonia—Doxorubicin—thyroid cancer	0.000374	0.00215	CcSEcCtD
Clodronate—SLC25A5—Disease—CALCA—thyroid cancer	0.000366	0.00305	CbGpPWpGaD
Clodronate—Renal failure—Doxorubicin—thyroid cancer	0.000366	0.0021	CcSEcCtD
Clodronate—Pharyngitis—Epirubicin—thyroid cancer	0.000358	0.00206	CcSEcCtD
Clodronate—Urinary tract disorder—Epirubicin—thyroid cancer	0.000356	0.00205	CcSEcCtD
Clodronate—Connective tissue disorder—Epirubicin—thyroid cancer	0.000355	0.00204	CcSEcCtD
Clodronate—Urethral disorder—Epirubicin—thyroid cancer	0.000354	0.00203	CcSEcCtD
Clodronate—SLC25A6—Metabolism—TPR—thyroid cancer	0.000343	0.00286	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PRKAR1A—thyroid cancer	0.000338	0.00281	CbGpPWpGaD
Clodronate—SLC25A5—Disease—CDK1—thyroid cancer	0.000332	0.00276	CbGpPWpGaD
Clodronate—Pharyngitis—Doxorubicin—thyroid cancer	0.000331	0.00191	CcSEcCtD
Clodronate—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—thyroid cancer	0.000331	0.00275	CbGpPWpGaD
Clodronate—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00033	0.0019	CcSEcCtD
Clodronate—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000328	0.00189	CcSEcCtD
Clodronate—Urethral disorder—Doxorubicin—thyroid cancer	0.000327	0.00188	CcSEcCtD
Clodronate—Mediastinal disorder—Epirubicin—thyroid cancer	0.000325	0.00187	CcSEcCtD
Clodronate—SLC25A4—Disease—TPR—thyroid cancer	0.00032	0.00266	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PRKAR1A—thyroid cancer	0.000315	0.00262	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CALCA—thyroid cancer	0.000307	0.00255	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—SLC5A5—thyroid cancer	0.000307	0.00255	CbGpPWpGaD
Clodronate—SLC25A4—Disease—MEN1—thyroid cancer	0.000301	0.00251	CbGpPWpGaD
Clodronate—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000301	0.00173	CcSEcCtD
Clodronate—Anaemia—Epirubicin—thyroid cancer	0.00029	0.00167	CcSEcCtD
Clodronate—PTGS2—Spinal Cord Injury—CDK1—thyroid cancer	0.000284	0.00236	CbGpPWpGaD
Clodronate—SLC25A6—Disease—CDK1—thyroid cancer	0.000278	0.00231	CbGpPWpGaD
Clodronate—Anaemia—Doxorubicin—thyroid cancer	0.000269	0.00154	CcSEcCtD
Clodronate—SLC25A4—Metabolism—TPR—thyroid cancer	0.000268	0.00223	CbGpPWpGaD
Clodronate—SLC25A5—Disease—NRG1—thyroid cancer	0.000266	0.00222	CbGpPWpGaD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000266	0.00153	CcSEcCtD
Clodronate—SLC25A4—Metabolism—PRKAR1A—thyroid cancer	0.000264	0.0022	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—RXRA—thyroid cancer	0.000258	0.00215	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—SLC5A5—thyroid cancer	0.000257	0.00214	CbGpPWpGaD
Clodronate—Infection—Epirubicin—thyroid cancer	0.000255	0.00146	CcSEcCtD
Clodronate—Skin disorder—Epirubicin—thyroid cancer	0.000249	0.00143	CcSEcCtD
Clodronate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000246	0.00141	CcSEcCtD
Clodronate—Anorexia—Epirubicin—thyroid cancer	0.000244	0.00141	CcSEcCtD
Clodronate—SLC25A4—Disease—CALCA—thyroid cancer	0.00024	0.00199	CbGpPWpGaD
Clodronate—SLC25A5—Disease—TERT—thyroid cancer	0.000239	0.00199	CbGpPWpGaD
Clodronate—Infection—Doxorubicin—thyroid cancer	0.000236	0.00136	CcSEcCtD
Clodronate—Skin disorder—Doxorubicin—thyroid cancer	0.00023	0.00132	CcSEcCtD
Clodronate—Dyspnoea—Epirubicin—thyroid cancer	0.000229	0.00131	CcSEcCtD
Clodronate—SLC25A5—Disease—HIF1A—thyroid cancer	0.000229	0.0019	CbGpPWpGaD
Clodronate—Anorexia—Doxorubicin—thyroid cancer	0.000226	0.0013	CcSEcCtD
Clodronate—Dyspepsia—Epirubicin—thyroid cancer	0.000226	0.0013	CcSEcCtD
Clodronate—SLC25A6—Disease—NRG1—thyroid cancer	0.000223	0.00186	CbGpPWpGaD
Clodronate—Decreased appetite—Epirubicin—thyroid cancer	0.000223	0.00128	CcSEcCtD
Clodronate—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000221	0.00127	CcSEcCtD
Clodronate—SLC25A4—Disease—CDK1—thyroid cancer	0.000217	0.00181	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000216	0.0018	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—RXRA—thyroid cancer	0.000216	0.0018	CbGpPWpGaD
Clodronate—Dyspnoea—Doxorubicin—thyroid cancer	0.000211	0.00122	CcSEcCtD
Clodronate—Dyspepsia—Doxorubicin—thyroid cancer	0.000209	0.0012	CcSEcCtD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000207	0.00172	CbGpPWpGaD
Clodronate—Decreased appetite—Doxorubicin—thyroid cancer	0.000206	0.00119	CcSEcCtD
Clodronate—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000206	0.00171	CbGpPWpGaD
Clodronate—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000205	0.00118	CcSEcCtD
Clodronate—Urticaria—Epirubicin—thyroid cancer	0.000204	0.00117	CcSEcCtD
Clodronate—Abdominal pain—Epirubicin—thyroid cancer	0.000203	0.00117	CcSEcCtD
Clodronate—SLC25A4—Metabolism—SLC5A5—thyroid cancer	0.000201	0.00167	CbGpPWpGaD
Clodronate—SLC25A6—Disease—TERT—thyroid cancer	0.0002	0.00167	CbGpPWpGaD
Clodronate—SLC25A6—Disease—HIF1A—thyroid cancer	0.000192	0.00159	CbGpPWpGaD
Clodronate—SLC25A5—Disease—BRAF—thyroid cancer	0.000189	0.00158	CbGpPWpGaD
Clodronate—Urticaria—Doxorubicin—thyroid cancer	0.000188	0.00108	CcSEcCtD
Clodronate—Abdominal pain—Doxorubicin—thyroid cancer	0.000188	0.00108	CcSEcCtD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000186	0.00155	CbGpPWpGaD
Clodronate—Pruritus—Epirubicin—thyroid cancer	0.000181	0.00104	CcSEcCtD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000179	0.00149	CbGpPWpGaD
Clodronate—Diarrhoea—Epirubicin—thyroid cancer	0.000175	0.00101	CcSEcCtD
Clodronate—SLC25A4—Disease—NRG1—thyroid cancer	0.000174	0.00145	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—RXRA—thyroid cancer	0.000169	0.0014	CbGpPWpGaD
Clodronate—Pruritus—Doxorubicin—thyroid cancer	0.000168	0.000965	CcSEcCtD
Clodronate—Vomiting—Epirubicin—thyroid cancer	0.000163	0.000937	CcSEcCtD
Clodronate—SLC25A5—Metabolism—PPARG—thyroid cancer	0.000163	0.00135	CbGpPWpGaD
Clodronate—Diarrhoea—Doxorubicin—thyroid cancer	0.000162	0.000933	CcSEcCtD
Clodronate—Rash—Epirubicin—thyroid cancer	0.000162	0.000929	CcSEcCtD
Clodronate—Dermatitis—Epirubicin—thyroid cancer	0.000161	0.000929	CcSEcCtD
Clodronate—SLC25A6—Disease—BRAF—thyroid cancer	0.000159	0.00132	CbGpPWpGaD
Clodronate—PTGS2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000158	0.00132	CbGpPWpGaD
Clodronate—SLC25A4—Disease—TERT—thyroid cancer	0.000156	0.0013	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—CCND1—thyroid cancer	0.000155	0.00129	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PTGS2—thyroid cancer	0.000153	0.00127	CbGpPWpGaD
Clodronate—Nausea—Epirubicin—thyroid cancer	0.000152	0.000876	CcSEcCtD
Clodronate—Vomiting—Doxorubicin—thyroid cancer	0.000151	0.000867	CcSEcCtD
Clodronate—Rash—Doxorubicin—thyroid cancer	0.00015	0.00086	CcSEcCtD
Clodronate—SLC25A4—Disease—HIF1A—thyroid cancer	0.000149	0.00124	CbGpPWpGaD
Clodronate—Dermatitis—Doxorubicin—thyroid cancer	0.000149	0.000859	CcSEcCtD
Clodronate—PTGS2—Disease—TRIM24—thyroid cancer	0.000145	0.00121	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—MINPP1—thyroid cancer	0.000143	0.00119	CbGpPWpGaD
Clodronate—Nausea—Doxorubicin—thyroid cancer	0.000141	0.00081	CcSEcCtD
Clodronate—PTGS2—Disease—CHST14—thyroid cancer	0.000137	0.00114	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PPARG—thyroid cancer	0.000136	0.00114	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—NRAS—thyroid cancer	0.000134	0.00111	CbGpPWpGaD
Clodronate—SLC25A5—Disease—PTEN—thyroid cancer	0.000133	0.00111	CbGpPWpGaD
Clodronate—PTGS2—Disease—TRIM33—thyroid cancer	0.00013	0.00108	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PTGS2—thyroid cancer	0.000128	0.00107	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PTGS2—thyroid cancer	0.000128	0.00107	CbGpPWpGaD
Clodronate—SLC25A4—Disease—BRAF—thyroid cancer	0.000124	0.00103	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—NDUFA13—thyroid cancer	0.000122	0.00101	CbGpPWpGaD
Clodronate—SLC25A5—Disease—NRAS—thyroid cancer	0.000119	0.00099	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—CCND1—thyroid cancer	0.000118	0.000984	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—KRAS—thyroid cancer	0.000115	0.000957	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—CHST14—thyroid cancer	0.000114	0.000953	CbGpPWpGaD
Clodronate—SLC25A6—Disease—PTEN—thyroid cancer	0.000112	0.00093	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—PTEN—thyroid cancer	0.000112	0.000929	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTGS2—thyroid cancer	0.000107	0.000893	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PPARG—thyroid cancer	0.000106	0.000886	CbGpPWpGaD
Clodronate—SLC25A5—Disease—KRAS—thyroid cancer	0.000102	0.000852	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PTGS2—thyroid cancer	0.0001	0.000832	CbGpPWpGaD
Clodronate—SLC25A6—Disease—NRAS—thyroid cancer	9.97e-05	0.00083	CbGpPWpGaD
Clodronate—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	9.78e-05	0.000814	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—PTEN—thyroid cancer	9.36e-05	0.000779	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—HPGD—thyroid cancer	9.23e-05	0.000768	CbGpPWpGaD
Clodronate—SLC25A4—Disease—PTEN—thyroid cancer	8.72e-05	0.000726	CbGpPWpGaD
Clodronate—SLC25A5—Disease—HRAS—thyroid cancer	8.7e-05	0.000724	CbGpPWpGaD
Clodronate—PTGS2—Disease—TCF7L1—thyroid cancer	8.65e-05	0.00072	CbGpPWpGaD
Clodronate—SLC25A6—Disease—KRAS—thyroid cancer	8.58e-05	0.000714	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTGS2—thyroid cancer	8.37e-05	0.000697	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	8.04e-05	0.00067	CbGpPWpGaD
Clodronate—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	7.79e-05	0.000648	CbGpPWpGaD
Clodronate—SLC25A4—Disease—NRAS—thyroid cancer	7.78e-05	0.000648	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	7.76e-05	0.000646	CbGpPWpGaD
Clodronate—SLC25A5—Disease—AKT1—thyroid cancer	7.68e-05	0.000639	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	7.49e-05	0.000623	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—PTEN—thyroid cancer	7.3e-05	0.000608	CbGpPWpGaD
Clodronate—SLC25A6—Disease—HRAS—thyroid cancer	7.29e-05	0.000607	CbGpPWpGaD
Clodronate—SLC25A4—Disease—KRAS—thyroid cancer	6.7e-05	0.000557	CbGpPWpGaD
Clodronate—SLC25A6—Disease—AKT1—thyroid cancer	6.44e-05	0.000536	CbGpPWpGaD
Clodronate—SLC25A5—Metabolism—AKT1—thyroid cancer	6.43e-05	0.000536	CbGpPWpGaD
Clodronate—PTGS2—Disease—TPR—thyroid cancer	6.33e-05	0.000527	CbGpPWpGaD
Clodronate—PTGS2—Disease—PRKAR1A—thyroid cancer	6.23e-05	0.000518	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	5.96e-05	0.000496	CbGpPWpGaD
Clodronate—PTGS2—Disease—MEN1—thyroid cancer	5.95e-05	0.000495	CbGpPWpGaD
Clodronate—SLC25A4—Disease—HRAS—thyroid cancer	5.69e-05	0.000474	CbGpPWpGaD
Clodronate—SLC25A6—Metabolism—AKT1—thyroid cancer	5.39e-05	0.000449	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—TPR—thyroid cancer	5.3e-05	0.000441	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	5.3e-05	0.000441	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PRKAR1A—thyroid cancer	5.21e-05	0.000434	CbGpPWpGaD
Clodronate—SLC25A4—Disease—AKT1—thyroid cancer	5.03e-05	0.000418	CbGpPWpGaD
Clodronate—PTGS2—Disease—CALCA—thyroid cancer	4.74e-05	0.000394	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.73e-05	0.000393	CbGpPWpGaD
Clodronate—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4.47e-05	0.000372	CbGpPWpGaD
Clodronate—PTGS2—Disease—CDK1—thyroid cancer	4.29e-05	0.000357	CbGpPWpGaD
Clodronate—SLC25A4—Metabolism—AKT1—thyroid cancer	4.21e-05	0.00035	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—SLC5A5—thyroid cancer	3.97e-05	0.00033	CbGpPWpGaD
Clodronate—PTGS2—Disease—NRG1—thyroid cancer	3.44e-05	0.000287	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—RXRA—thyroid cancer	3.33e-05	0.000277	CbGpPWpGaD
Clodronate—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.24e-05	0.00027	CbGpPWpGaD
Clodronate—PTGS2—Disease—TERT—thyroid cancer	3.09e-05	0.000257	CbGpPWpGaD
Clodronate—PTGS2—Disease—HIF1A—thyroid cancer	2.96e-05	0.000246	CbGpPWpGaD
Clodronate—PTGS2—Disease—BRAF—thyroid cancer	2.45e-05	0.000204	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PPARG—thyroid cancer	2.1e-05	0.000175	CbGpPWpGaD
Clodronate—PTGS2—Disease—PTEN—thyroid cancer	1.72e-05	0.000144	CbGpPWpGaD
Clodronate—PTGS2—Disease—NRAS—thyroid cancer	1.54e-05	0.000128	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—PTEN—thyroid cancer	1.44e-05	0.00012	CbGpPWpGaD
Clodronate—PTGS2—Disease—KRAS—thyroid cancer	1.32e-05	0.00011	CbGpPWpGaD
Clodronate—PTGS2—Disease—HRAS—thyroid cancer	1.13e-05	9.37e-05	CbGpPWpGaD
Clodronate—PTGS2—Disease—AKT1—thyroid cancer	9.94e-06	8.27e-05	CbGpPWpGaD
Clodronate—PTGS2—Metabolism—AKT1—thyroid cancer	8.32e-06	6.93e-05	CbGpPWpGaD
